Luteolin exerts an anticancer effect on NCI-H460 human non-small cell lung cancer cells through the induction of Sirt1-mediated apoptosis

Molecular Medicine Reports

Volumn 12, Issue 3, 2015, Pages 4196-4202

  Ma, Liping ^a   Peng, Hongjun ^b   Li, Kunsheng ^c   Zhao, Runrun ^c   Li, Li ^c   Yu, Yilong ^c   Wang, Xiaoming ^c   Han, Zhifeng ^c  

^a THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Luteolin; Non small cell lung cancer; Sirt1

Indexed keywords

CASPASE 3; LUTEOLIN; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; SHORT HAIRPIN RNA; SIRTUIN 1; ANTINEOPLASTIC AGENT; SIRT1 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER CELL LINE; METASTASIS; METASTASIS INHIBITION; MIGRATION INHIBITION; NCI H460 CELL LINE; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; CELL MOTION; CHEMISTRY; DRUG EFFECTS; G1 PHASE CELL CYCLE CHECKPOINT; GENETICS; HEK293 CELL LINE; LUNG TUMOR; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

LENTIVIRUS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-ASSOCIATED DEATH PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CELL LINE, TUMOR; CELL MOVEMENT; G1 PHASE CELL CYCLE CHECKPOINTS; HEK293 CELLS; HUMANS; LUNG NEOPLASMS; LUTEOLIN; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIRTUIN 1;

EID: 84935519165     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3956     Document Type: Article

References (24)

1. Szyszka-Barth K, Ramlau K, Gozdzik-Spychalska J, et al: Actual status of therapeutic vaccination in non-small cell lung cancer. Contemp Oncol (Pozn) 18:77-84, 2014.
2. Lin Y, Shi R, Wang X and Shen HM: Luteolin, a flavonoid with potentials for cancer prevention and therapy. Curr Cancer Drug Targets 8:634-646, 2008.
3. Lin Y, Shi R, Wang X and Shen HM: Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets 8:634-646, 2008.
4. Asgarpanah J and Kazemivash N: Phytochemistry, pharmacology and medicinal properties of Carthamus tinctorius L. Chin J Integr Med 19:153-159, 2013.
5. Cai X, Ye T, Liu C, et al: Luteolin induced G2 phase cell cycle arrest and apoptosis on non-small cell lung cancer cells. Toxicol In Vitro 25:1385-1391, 2011.
6. Heltweg B, Gatbonton T, Schuler AD, et al: Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 66:4368-4377, 2006.
7. Chen HC, Jeng YM, Yuan RH, Hsu HC and Chen YL: SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis. Ann Surg Oncol 19:2011-2019, 2012.
8. Pang WJ, Xiong Y, Wang Y, Tong Q and Yang GS: Sirt1 attenuates camptothecin-induced apoptosis through caspase-3 pathway in porcine preadipocytes. Exp Cell Res 319:670-683, 2013.
9. Yi J and Luo J: SIRT1 and p53, effect on cancer, senescence and beyond. Biochim Biophys Acta 1804:1684-9, 2010.
10. Gao Z and Ye J: Inhibition of transcriptional activity of c-JUN by SIRT1. Biochem Biophys Res Commun 376:793-796, 2008.
11. Shi H, Wang J, Dong F, Wang X, Li H and Hou Y: The effect of proteoglycans inhibited by RNA interference on metastatic characters of human salivary adenoid cystic carcinoma. BMC Cancer 9:456, 2009.
12. Daoud A, Song J, Xiao F and Shang J: B-9-3, a novel beta-carboline derivative exhibits anti-cancer activity via induction of apoptosis and inhibition of cell migration in vitro. Eur J Pharmacol 724:219-230, 2014.
13. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) Method[J]. Methods 25:402-408, 2001.
14. Yamaguchi H, Wyckoff J and Condeelis J: Cell migration in tumors. Curr Opin Cell Biol 17:559-564, 2005.
15. Sahai A, Mallina R, Dowson C, Larner T and Khan MS: Evolution of transdermal oxybutynin in the treatment of overactive bladder. Int J Clin Pract 62:167-170, 2008.
16. Park SH, Park HS, Lee JH, et al: Induction of endoplasmic reticulum stress-mediated apoptosis and non-canonical autophagy by luteolin in NCI-H460 lung carcinoma cells. Food Chem Toxicol 56:100-109, 2013.
17. Kollipara PS, Jeong HS, Han SB and Hong JT: (E)-2, 4-bis (p-hydroxyphenyl)-2-butenal has an antiproliferative effect on NSCLC cells induced by p38 MAPK-mediated suppression of NF-kappaB and up-regulation of TNFRSF10B (DR5). Br J Pharmacol 168:1471-1484, 2013.
18. Yeung F, Hoberg JE, Ramsey CS, et al: Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23:2369-2380, 2004.
19. Sun Y, Sun D, Li F, et al: Downregulation of Sirt1 by antisense oligonucleotides induces apoptosis and enhances radiation sensitization in A549 lung cancer cells. Lung Cancer 58:21-29, 2007.
20. Chen MC, Chen CH, Liu YN, Wang HP, Pan SL and Teng CM: TW01001, a novel piperazinedione compound, induces mitotic arrest and autophagy in non-small cell lung cancer A549 cells. Cancer Lett 336:370-378, 2013.
21. Chian S, Thapa R, Chi Z, Wang XJ and Tang X: Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo. Biochem Biophys Res Commun 447:602-608, 2014.
22. Bai L, Xu X, Wang Q, et al: A superoxide-mediated mitogen-activated protein kinase phosphatase-1 degradation and c-Jun. NH2-terminal kinase activation pathway for luteolin-induced lung cancer cytotoxicity. Mol Pharmacol 81:549-555, 2012.
23. Solomon JM, Pasupuleti R, Xu L, et al: Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol 26:28-38, 2006.
24. Liu X, Shao K and Sun T: SIRT1 regulates the human alveolar epithelial A549 cell apoptosis induced by Pseudomonas aeruginosa lipopolysaccharide. Cell Physiol Biochem 31:92-101, 2013.